Patents & Products

7. Small Molecules that Inhibit RNA Binding Protein IGF2BP3 in Cancer. Dinesh R. Rao, Robert Damoiseaux, Neil K. Garg, Amit K. Jaiswal, Georgia M. Scherer, Jacob P. Sorrentino, Michelle L. Thaxton. Provisional Patent 63/528,250. PCT # PCT/US24/39005.

6. Methods for the Preparation of Hexahydrocannabinol. Neil K. Garg and Daniel J. Nasrallah. Provisional Patent Application filed (2023). 

5. Systems and Methods for the Detection of Phenolic Cannabinoids. Neil K. Garg and Evan R. Darzi. US Patent Application No. US2020/058535; European Patent Application No. 20882717.0; Canadian Patent Application No. 3,155,790; ; Australian Patent Application No. 2020373122.

4. Methods for the Synthesis of Heteroatom Containing Polycyclic Aromatic Hydrocarbons. Robert B. Susick, Jason V. Chari, Katie S. Spence, Neil K. Garg, Evan R. Darzi, and Joyann S. Barber. US Patent Application No. US2021/0323987. 

3. Compositions and Methods for the Treatment of Neurodegenerative Diseases. Varghese John, Tina Bilousova, Bryan Simmons, Neil Garg, Jesus Campagna, and Barbara Jagodzinska. International Patent Application No. WO2021/142221. 

2. Amination of Aryl Alcohol Derivatives. Neil K. Garg, Stephen D. Ramgren, Amanda L. Silberstein, and Kyle W. Quasdorf. US Patent US9567307. 

1. Cross-Coupling of Phenolic Derivatives. Neil K. Garg, Kyle W. Quasdorf, and Xia Tian. US Patent US8546607. 

Our laboratory has developed several widely used technologies. Industrial giants such as Genentech, Roche, Lilly, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Merck, Novartis, and FMC are among the many users of our chemistry.

For our commercially available precursors to strained intermediates or wax-encapsulated nickel catalysts, see the links below.